Mesenchymal Stem Cells - Advances And Applications

1
Mesenchymal Stem Cells - Advances And
Applications
2
Summary
This global strategic report is produced for
Management of stem cell companies Management of
regenerative therapy companies Stem cell
industry investorsIt is designed to increase
your efficiency and effectiveness in1.
Commercializing mesenchymal stem cell (MSC)
products, technologies, and therapies2. Making
intelligent investment decisions3. Launching
high-demand products4. Selling effectively to
your client base5. Increasing revenue from MSC
products and services6. Taking market share from
your competition
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
3
Mesenchymal stem cells (MSCs) are multipotent
stem cells that can differentiate into a variety
of cell types, including osteoblasts,
chondrocytes, myocytes, adipocytes,
beta-pancreatic islets cells, and potentially,
neuronal cells. MSCs are of intense therapeutic
interest because they represent a population of
cells with the potential to treat a wide range of
acute and degenerative diseases.MSCs are
advantageous over other stem cells types for a
variety of reasons they avoid the ethical issues
that surround embryonic stem cell research, and
repeated studies have found MSCs to be
immuno-privileged, which make them an
advantageous cell type for allogenic
transplantation. MSCs reduce both the risks of
rejection and complications of transplantation.
Recently, there have been advances in the use of
autologous mesenchymal stem cells to regenerate
human tissues, including cartilage, meniscus,
tendons, bone fractures, and more.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
4
This global strategic report explores recent
advances in MSC research applications, research
priorities by market segment, and the competitive
environment for MSC research products. It also
identifies trend and growth patterns within the
MSC industry. Because it is important for
pharmaceutical companies interested to understand
underlying forces affecting the MSC market, this
report also presents a range of topics that apply
to these companies, including how advances in MSC
research can reveal potential new drug targets,
improve methods of drug delivery, and provide
personalized treatment strategies.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
5
Literature and data concerning the biology and
differentiation potential of mesenchymal stem
cells (MSCs) has expanded rapidly over the past
10 years, with more than 13,000 publications now
exploring aspects of MSC biology, behavior, and
applications. In particular, MSCs appear to be an
exceptionally promising tool for cell therapy
because of their unusual characteristics, which
partially mimic those of embryonic stem cells,
while having advantages in terms of availability,
expandability, transplantability, and ethical
implications.Interest in therapeutic
applications of human MSCs arises from their
diverse ability to differentiate into a range of
cell types, as well as from their ability to
migrate to sites of tissue injury/inflammation or
tumor growth. These localization properties
present a promising strategy for targeted
introduction of therapeutic agents through MSC
gene therapy. In addition, MSCs possess strong
immunosuppressive properties that medical
researchers are exploiting for both autologous as
well as heterologous therapies.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
6
Clinical Progress with MSCsAs mentioned,
mesenchymal stem cells (MSCs) have inspired a lot
of activity over the past ten years as a novel
therapeutic model for a wide range of diseases.
Presently, MSCs-based clinical trials are being
conducted for twelve types of disease conditions,
with many completed trials showing their safety
and efficacy. The clinical utility of MSCs are
mostly attributed to their four key biological
properties, which are their potential to 1.
Migrate to sites of inflammation caused by tissue
injury when injected intravenously2. To get
differentiated into different cell types3. To
release different bioactive molecules having the
potential of stimulating recovery of injured
cells and preventing inflammation4. To
accomplish immunomodulatory functions
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
7
Currently, there are 128 clinical trials
involving MSCs are in progress in different parts
of the world, including China, the European
Union, the United States, the Middle East, and
South Korea. Among these trials, 45 (35) are
exploiting MSCs for various disease indications.
Currently, four major clinical trials using MSCs
have reached Phase III. Stempeutics Researchs
product candidate Stempeucel is being evaluated
in two centers for treating critical leg
ischemia. Prochymal is the product candidate from
Osiris Therapeutics and it is being used for
treating graft vs. host disease (GvHD). The
company is also testing Prochymal for treating
Crohns disease in another Phase III trial. The
Australian company Mesoblast is testing an
off-the-shelf mesenchymal precursor product
candidate for treating patients with
hematological malignancies.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
8
Table of Contents
1. REPORT OVERVIEW 1.1 Statement of the Report
1.2 EXECUTIVE SUMMARY 2. INTRODUCTION 2.1
Regenerative Medicine (RM) and Advanced Therapies
Industry A Brief Overview 2.2 Global Breakdown
of Major RM Industries by Region 2.3 Breakdown
of Global RM Companies by Type 2.4 Number of
Therapeutic Companies, Approved Products and
Clinical Trials in RM Sector 2.5 Number of RM
Clinical Trials by Phase of Development
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
9
To view the full Executive Summary and Table of
Contents, please visit Mesenchymal Stem Cells
- Advances And Applications Contact UsBharat
Book BureauCall us 91-22-27810772 / 73Email
id info_at_bharatbook.com Blog
https//www.bharatbook.com/blog/
Follow Us On